Section Arrow
Quote
ENGN.NASDAQ
- enGene Therapeutics Inc
Quotes are at least 15-min delayed:2026/04/26 01:19 EDT
Regular Hours
Last
 7.99
-0.15 (-1.84%)
Day High 
8.34 
Prev. Close
8.14 
1-M High
8.85 
Volume 
222.24K 
Bid
3.26
Ask
12.5
Day Low
7.687 
Open
8.02 
1-M Low
6.05 
Market Cap 
545.29M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 7.99 
20-SMA 7.44 
50-SMA 8.17 
52-W High 12.25 
52-W Low 2.65 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.25/-1.75
Enterprise Value
567.07M
Balance Sheet
Book Value Per Share
4.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SCNIScinai Immunotherapeutics Ltd.0.737+0.281+61.62%0.15PE
ENVBEnveric Biosciences Inc.5.04+1.02+25.37%0PE
SGMOSangamo Therapeutics0.1901-0.0649-25.45%-- 
LNAILunai Bioworks Inc.0.3101+0.0054+1.77%-- 
IBRXImmunityBio7.44-0.75-9.16%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGENDPhase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.